Shares of Prime Medicine(NASDAQ: PRME) are surging on Thursday. The gene-editing company's stock gained 10.5% as of 2 p.m. ET and was up as much as 17% earlier in the day. The move up comes as the S&P 500 and Nasdaq Composite gained 0.4% and 0.7%, respectively.

The clinical-stage biotech unveiled a promising new preclinical program targeting a serious disorder of the lungs and liver.

New gene-editing program revealed

Prime Medicine announced yesterday a new preclinical program for treating alpha-1 antitrypsin deficiency (AATD), a genetic disorder affecting lung and liver function. The announcement included plans to file an Investigational New Drug Application or Clinical Trial Application with the FDA by mid-2026.

Prime's universal liver lipid nanoparticle (LNP) technology is at the cutting edge of gene therapy. It will be used to edit the SERPINA1 gene, which when mutated is responsible for the condition.

Investors are reacting to the expectations of trials beginning by 2026 as well as compelling early data presented by the company in the release.

It is still early

Though the announcement brings some excitement, Prime Medicine is still a clinical-stage biotech company with substantial development risks ahead. A lot can go wrong in the course of developing new therapies. Even if it all goes according to plan, commercialization is years down the line and there is no guarantee another company won't beat it to the punch.

However, the company does have a portfolio of therapies further along in the pipeline and it does have impressive proprietary technology. If you are an investor with a high risk tolerance, Prime could be an interesting addition to your portfolio.

Don’t miss this second chance at a potentially lucrative opportunity

Ever feel like you missed the boat in buying the most successful stocks? Then you’ll want to hear this.

On rare occasions, our expert team of analysts issues a “Double Down” stock recommendation for companies that they think are about to pop. If you’re worried you’ve already missed your chance to invest, now is the best time to buy before it’s too late. And the numbers speak for themselves:

Nvidia:if you invested $1,000 when we doubled down in 2009,you’d have $299,339!* Apple: if you invested $1,000 when we doubled down in 2008, you’d have $40,324!* Netflix: if you invested $1,000 when we doubled down in 2004, you’d have $501,530!*

Right now, we’re issuing “Double Down” alerts for three incredible companies, and there may not be another chance like this anytime soon.

Story Continues

Continue »

*Stock Advisor returns as of March 18, 2025

Johnny Rice has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Why Prime Medicine Stock Is Soaring Today was originally published by The Motley Fool

View Comments